ZELIRA THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.71 AUD | +1.43% |
|
0.00% | -21.11% |
Presenter SpeechOsagie Imasogie (Executives)It is now 9 a.m. I am delighted to welcome all sha...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.11% | 5.23M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.75% | 22.2B | |
| -16.53% | 21.23B | |
| -9.00% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- ZLD Stock
- News Zelira Therapeutics Limited
- Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call
